Enanta Pharmaceuticals (ENTA) Liabilities and Shareholders Equity (2012 - 2026)

Enanta Pharmaceuticals (ENTA) has 15 years of Liabilities and Shareholders Equity data on file, last reported at $314.7 million in Q1 2026.

• For the quarter ending Q1 2026, Liabilities and Shareholders Equity fell 2.57% year-over-year to $314.7 million; the trailing twelve-month figure through Mar 2026 stood at $1.2 billion (down 15.28% YoY), and the FY2025 full-year result was $280.7 million, down 25.47% from the prior year.
• Liabilities and Shareholders Equity for Q1 2026 stood at $314.7 million, down from $329.5 million in the prior quarter.
• Across five years, Liabilities and Shareholders Equity topped out at $495.2 million in Q2 2023 and bottomed at $280.7 million in Q3 2025.
• The 5-year median for Liabilities and Shareholders Equity is $375.4 million (2022), against an average of $371.4 million.
• The widest annual swing landed in 2023, when Liabilities and Shareholders Equity climbed 28.54%; it then retreated 25.47% in 2025.
• A 5-year view of Liabilities and Shareholders Equity shows it stood at $347.5 million in 2022, then climbed by 23.3% to $428.5 million in 2023, then decreased by 18.64% to $348.6 million in 2024, then slipped by 5.49% to $329.5 million in 2025, then retreated by 4.49% to $314.7 million in 2026.
• The last three Liabilities and Shareholders Equity figures came in at $314.7 million (Q1 2026), $329.5 million (Q4 2025), and $280.7 million (Q3 2025), per Business Quant data.

Peer Comparison